ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) — Stereotaxis STXS, a pioneer and world chief in surgical robotics for minimally invasive endovascular intervention, immediately introduced that its expertise might be prominently featured in the course of the upcoming HRX digital well being convention happening September 5-7, 2024, in Atlanta, Georgia.
HRX, an initiative pioneered by the Coronary heart Rhythm Society (HRS), is concentrated on exploring digital applied sciences that advance the boundaries of innovation in cardiovascular drugs.
Stereotaxis CEO, David Fischel, will take part in a roundtable dialogue titled “The EP Lab of the Future” on September fifth starting at 4:45 PM EDT. On September sixth at 9:45 AM EDT, Mr. Fischel will be a part of a distinguished panel of specialists, together with Dr. Ben D’Souza, Dr. Dan Cooper, and Dr. Peter Weiss for a Joint Session of the Society of Cardiac Robotic Navigation and HRS titled “The Function of Robotics in Current and Future Care of Coronary heart Rhythm Sufferers.” These periods spotlight the rising consciousness and relevance of robotic expertise in bettering affected person outcomes and advancing the sector of cardiac rhythm administration.
“We respect the chance to take part in these discussions with the HRX neighborhood as we collectively outline a future wherein sufferers and suppliers profit from the promise of robotics, connectivity, and digital improvements,” mentioned David Fischel.
About Stereotaxis
Stereotaxis STXS is a pioneer and world chief in progressive surgical robotics for minimally invasive endovascular intervention. Its mission is the invention, growth and supply of robotic methods, devices, and knowledge options for the interventional laboratory. These improvements assist physicians present unsurpassed affected person care with robotic precision and security, increase entry to minimally invasive remedy, and improve the productiveness, connectivity, and intelligence within the working room. Stereotaxis expertise has been used to deal with over 100,000 sufferers throughout the US, Europe, Asia, and elsewhere. For extra data, please go to www.stereotaxis.com.
This press launch consists of statements that will represent “forward-looking” statements, often containing the phrases “imagine”, “estimate”, “undertaking”, “count on” or comparable expressions. Ahead-looking statements inherently contain dangers and uncertainties that would trigger precise outcomes to vary materially. Components that will trigger or contribute to such variations embrace, however aren’t restricted to, the Firm’s potential to handle bills at sustainable ranges, acceptance of the Firm’s merchandise within the market, the impact of world financial situations on the flexibility and willingness of consumers to buy its expertise, aggressive elements, modifications ensuing from healthcare coverage, dependence upon third-party distributors, timing of regulatory approvals, the affect of pandemics or different disasters, and statements referring to our latest acquisition of APT, together with any advantages anticipated from the acquisition, and different dangers mentioned within the Firm’s periodic and different filings with the Securities and Change Fee. By making these forward-looking statements, the Firm undertakes no obligation to replace these statements for revisions or modifications after the date of this launch. There could be no assurance that the Firm will acknowledge income associated to its buy orders and different commitments as a result of a few of these buy orders and different commitments are topic to contingencies which are exterior of the Firm’s management and could also be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Govt Officer
Kimberly Peery
Chief Monetary Officer
314-678-6100
[email protected]
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
